Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Paris, October 19, 2023. Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti. Enoxaparin Sodium Impact is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis, a potentially lethal disease often underdiagnosed on the African continent. With this first shipment to Djibouti, Sanofi delivers on its commitment to improve and accelerate affordable and sustainable access to quality medicines, vaccines and healthcare for underserved populations.

Sanofi's social model to broaden access is channeled through its Global Health Unit (GHU). The first global initiative of its kind, Sanofi’s GHU aims to provide access to a broad portfolio of medicines in 40 countries with the highest unmet medical needs. To that point, the GHU created Impact, a unique not-for-profit brand with 30 standard-of-care medicines produced by Sanofi, some of which are considered "essential" by the World Health Organization (WHO). The Impact medicines cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.

Head, Global Health Unit, Sanofi

“I'm delighted to see the very first Impact brand medicine, Enoxaparin Sodium Impact, arrive on Djibouti soil. This is an important milestone in Sanofi’s long-term objective to reach 2 million people with noncommunicable diseases in underserved populations by 2030. But providing access to quality medicines and sustainable healthcare to people in the 40 most underserved countries is not a simple task. It requires cross-sector partnerships on a global, regional, and importantly, on a local scale – work Sanofi does on the ground with the GHU teams. After Djibouti, we are now heading to Tanzania, scheduled to be the second country to receive an Impact brand medicine: Insulin Glargine Impact.”

The delivery of Enoxaparin Sodium Impact comes months after the signature of a partnership with the Republic of Djibouti’s Caisse Nationale de Sécurité Sociale (CNSS), the national social security fund. The partnership aims at improving diagnosis and management of cardiometabolic diseases and diabetes in Djibouti and to help local communities gain sustainable access to quality medicines at accessible pricing, medical training and capacity building.

Managing Director, Caisse Nationale de Sécurité Sociale, Djibouti

In partnership with Sanofi’s Global Health Unit, we are working to remove barriers that limit access to quality treatment and care for noncommunicable disease patients in Djibouti. The availability of Enoxaparin Sodium Impact at accessible pricing addresses an unmet need in the management of venous thromboembolic disease, a condition often underdiagnosed. Moreover, working with Sanofi within the local community to help train healthcare professionals, drive awareness around the management of cardiometabolic diseases and diabetes, and build capacity is critical to improving patient outcomes throughout the country.

Ahead of the delivery of the first not-for-profit Impact brand medicines, Sanofi’s Global Health Unit has been working closely with local communities, authorities and non-governmental organizations to support the set up and development of sustainable healthcare systems for those who suffer from chronic diseases and require complex care, and to develop disease awareness programs. To date, over 1,800 healthcare professionals have been trained in GHU-sponsored programs globally.

Tanzania is scheduled to be the second country to receive an Impact brand medicine : Insulin Glargine Impact

The WHO estimates over 4.5 billion people, or half the world's population, lacks coverage for essential health services1. According to the WHO, noncommunicable diseases (NCDs) are responsible for 41 million people dying each year, with low- and middle-income countries accounting for 77% of all NCDs deaths2.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Victor Rouault | + 33 6 70 93 71 40 | [email protected]

Evan Berland | +1 215 432 0234 | [email protected]

Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected]

Eva Schaefer-Jansen | + 33 7 86 80 56 39 | [email protected]

Arnaud Delépine | + 33 6 73 69 36 93 | [email protected]

Corentine Driancourt | + 33 6 40 56 92 21 | [email protected]

Felix Lauscher | + 1 908 612 7239 | [email protected]

Tarik Elgoutni| + 1 617 710 3587 | [email protected]

Nathalie Pham | + 33 7 85 93 30 17 | [email protected]

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and

Cautionary Statement Regarding Forward-Looking Statements

in Sanofi’s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

1 https://www.who.int/news-room/fact-sheets/detail/universal-hea...(uhc)

2 https://www.who.int/news-room/fact-sheets/detail/noncommunicab...